secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001193125-22-005116
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma reports $280.8M cash; pipeline milestones extend into 2023
----------------------------------------------------------------------

- Cash, cash equivalents and investments of $280.8M as of Dec 31, 2021; funds operations into first half of 2024.
- ORIC-101 Phase 1b updates from two combination trials expected in first half of 2022.
- Initial Phase 1b data for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate cancer) expected in first half of 2023.
- Two discovery programs advanced into lead optimization; new program/indication to be announced in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312522005116/0001193125-22-005116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312522005116/d243804d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-005116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer